H. Maurer

发表

Mass spectrometric approaches in impaired driving toxicology

H. Maurer, 2009, Analytical and bioanalytical chemistry.

Current role of liquid chromatography–mass spectrometry in clinical and forensic toxicology

H. Maurer, 2007, Analytical and bioanalytical chemistry.

Advances in analytical toxicology: the current role of liquid chromatography–mass spectrometry in drug quantification in blood and oral fluid

Hans H Maurer, H. Maurer, 2005, Analytical and bioanalytical chemistry.

Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control

Hans H Maurer, H. Maurer, 2004, Clinical chemistry and laboratory medicine.

Negative Ion Chemical Ionization Gas Chromatography-Mass Spectrometry and Atmospheric Pressure Chemical Ionization Liquid Chromatography-Mass Spectrometry of Low-Dosed and/or Polar Drugs in Plasma

F. Peters, H. Maurer, T. Kraemer, 2002, Therapeutic drug monitoring.

Systematic toxicological analysis of drugs and their metabolites by gas chromatography-mass spectrometry.

H. Maurer, 1992, Journal of chromatography.

Liquid chromatography-mass spectrometry in forensic and clinical toxicology.

H. Maurer, H H Maurer, Hans H. Maurer, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept

M. Meyer, H. Maurer, A. Weber, 2011, Analytical and bioanalytical chemistry.

Post-modern Medicolegal and Forensic Toxicology

H. Maurer, 2017 .

Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class.

M. Meyer, J. Dinger, H. Maurer, 2016, Toxicology letters.

In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach

M. Meyer, J. Dinger, H. Maurer, 2016, Archives of Toxicology.

Toxicokinetics-Variations due to Genetics or Interactions : Basics and Examples

H. Maurer, 2008 .

New psychoactive substances: Studies on the metabolism of XLR-11, AB-PINACA, FUB-PB-22, 4-methoxy-α-PVP, 25-I-NBOMe, and meclonazepam using human liver preparations in comparison to primary human hepatocytes, and human urine.

M. Meyer, H. Maurer, Lilian H. J. Richter, 2017, Toxicology letters.

Pooled human liver preparations, HepaRG, or HepG2 cell lines for metabolism studies of new psychoactive substances? A study using MDMA, MDBD, butylone, MDPPP, MDPV, MDPB, 5‐MAPB, and 5‐API as examples

V. Flockerzi, M. Meyer, H. Maurer, 2017, Journal of pharmaceutical and biomedical analysis.

Chapter 6 Sedatives and hypnotics

H. Maurer, T. Kraemer, 2008 .

Prevalence of illicit drug use in plasmapheresis donors

F. Peters, H. Maurer, P. Hellstern, 2003, Vox sanguinis.

Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine and N-(1-phenylcyclohexyl)-3-methoxypropanamine.

M. Meyer, F. Peters, H. Maurer, 2008, Chemical research in toxicology.

The in Vivo TRPV6 Protein Starts at a Non-AUG Triplet, Decoded as Methionine, Upstream of Canonical Initiation at AUG*

A. Beck, V. Flockerzi, U. Wissenbach, 2013, The Journal of Biological Chemistry.

Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatography–linear ion-trap (high-resolution) mass spectrometry

M. Meyer, H. Maurer, Carina Lindauer, 2014, Analytical and Bioanalytical Chemistry.

Intrahepatic Cholestasis Following Abuse of Powdered Kratom (Mitragyna speciosa)

V. Auwärter, H. Maurer, M. Hermanns-Clausen, 2011, Journal of Medical Toxicology.

Toxicokinetics of Amphetamines: Metabolism and Toxicokinetic Data of Designer Drugs, Amphetamine, Methamphetamine, and Their N-Alkyl Derivatives

H. Maurer, T. Kraemer, 2002, Therapeutic drug monitoring.

Chapter 8 Non-opioid analgesics

H. Maurer, T. Kraemer, 2008 .

Chapter 12 Forensic screening with GC-MS

H. Maurer, 2008 .

Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7.

F. Peters, H. Maurer, M. Bureik, 2011, Biochimica et biophysica acta.

Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid

R. Müller, A. Zöllner, H. Bode, 2009, Biological chemistry.

Phase I and II metabolites of speciogynine, a diastereomer of the main Kratom alkaloid mitragynine, identified in rat and human urine by liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry.

H. Maurer, A. Weber, D. Wissenbach, 2010, Journal of mass spectrometry : JMS.

Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine.

M. Huestis, M. Meyer, H. Maurer, 2011, Journal of mass spectrometry : JMS.

Further Studies on the Role of Metabolites in (±)-3,4-Methylenedioxymethamphetamine-Induced Serotonergic Neurotoxicity

U. McCann, G. Ricaurte, F. Peters, 2009, Drug Metabolism and Disposition.

Further Studies on the Role of Metabolites in MDMA-induced Serotonergic Neurotoxicity

U. McCann, G. Ricaurte, F. Peters, 2009 .

Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MSn, and LC-HR-MS/MS

M. Meyer, H. Maurer, S. Brandt, 2017, Analytical and Bioanalytical Chemistry.

Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract

M. Meyer, A. Becker, H. Maurer, 2013, Psychopharmacology.

The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence

M. Uder, M. Böhm, R. Schmieder, 2016, Journal of hypertension.

Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis

M. Burnier, M. Böhm, U. Laufs, 2015, Clinical Research in Cardiology.

Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening - exemplified for cardiovascular drugs.

M. Meyer, H. Maurer, A. Weber, 2015, Analytica chimica acta.

Screening for the detection of angiotensin-converting enzyme inhibitors, their metabolites, and AT II receptor antagonists.

H. Maurer, T. Kraemer, J. W. Arlt, 1998, Therapeutic drug monitoring.

The NTCP‐inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics

W. Haefeli, M. Meyer, M. Haag, 2018, Clinical pharmacology and therapeutics.

Systematic comparison of bias and precision data obtained with multiple-point and one-point calibration in six validated multianalyte assays for quantification of drugs in human plasma.

F. Peters, H. Maurer, 2007, Analytical chemistry.

Chemistry, Pharmacology, and Metabolism of Emerging Drugs of Abuse

H. Maurer, 2010, Therapeutic drug monitoring.

Perspectives of Liquid Chromatography Coupled to Low- and High-Resolution Mass Spectrometry for Screening, Identification, and Quantification of Drugs in Clinical and Forensic Toxicology

H. Maurer, 2010, Therapeutic drug monitoring.

Metabolism of designer drugs of abuse: an updated review.

M. Meyer, H. Maurer, 2010, Current drug metabolism.

Development of a quantitative approach in blood plasma for low-dosed hallucinogens and opioids using LC-high resolution mass spectrometry.

M. Meyer, H. Maurer, Andreas Kollas, 2018, Talanta.

Bioanalytical Methods for New Psychoactive Substances.

H. Maurer, Lea Wagmann, 2018, Handbook of experimental pharmacology.

A simple extraction and LC-MS/MS approach for the screening and identification of over 100 analytes in eight different matrices.

P. Schmidt, H. Maurer, M. Hopf, 2015, Drug testing and analysis.

Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.

M. Meyer, H. Maurer, S. Brandt, 2017, Drug testing and analysis.

Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC–MS, LC–MSn, and LC–HR–MS–MS

M. Meyer, H. Maurer, S. Brandt, 2015, Analytical and Bioanalytical Chemistry.

In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures

Madeleine Pettersson Bergstrand, M. Meyer, H. Maurer, 2019, Analytical and Bioanalytical Chemistry.

Validated liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in squirrel monkey plasma.

G. Ricaurte, F. Peters, H. Maurer, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Very Low Ethanol Concentrations Affect the Viability and Growth Recovery in Post-Stationary-Phase Staphylococcus aureus Populations

H. Sahl, I. Chatterjee, G. Somerville, 2006, Applied and Environmental Microbiology.

A multi-analyte approach to help in assessing the severity of acute poisonings - Development and validation of a fast LC-MS/MS quantification approach for 45 drugs and their relevant metabolites with one-point calibration.

H. Maurer, Julian A Michely, 2018, Drug testing and analysis.

Full validation and application of an ultra high performance liquid chromatographic-tandem mass spectrometric procedure for target screening and quantification of 34 antidepressants in human blood plasma as part of a comprehensive multi-analyte approach

M. Meyer, H. Maurer, D. Wissenbach, 2011, Analytical and bioanalytical chemistry.

Screening for and validated quantification of phenethylamine-type designer drugs and mescaline in human blood plasma by gas chromatography/mass spectrometry.

F. Peters, H. Maurer, V. Habrdová, 2005, Journal of mass spectrometry : JMS.

Fast, Simple, and Validated Gas Chromatographic-Mass Spectrometric Assay for Quantification of Drugs Relevant to Diagnosis of Brain Death in Human Blood Plasma Samples

F. Peters, H. Maurer, T. Kraemer, 2005, Therapeutic drug monitoring.

Review : Bioanalytical method validation – How , how much and why ?

F. Peters, H. Maurer, 2002 .

Studies on the metabolism of the Delta9-tetrahydrocannabinol precursor Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques.

M. Meyer, C. Neusüss, W. Weinmann, 2009, Journal of mass spectrometry : JMS.

Studies on the metabolism and toxicological detection of glaucine, an isoquinoline alkaloid from Glaucium flavum (Papaveraceae), in rat urine using GC-MS, LC-MS(n) and LC-high-resolution MS(n).

M. Meyer, H. Maurer, D. Wissenbach, 2013, Journal of mass spectrometry : JMS.

Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse.

M. Meyer, H. Maurer, J. Zapp, 2013, Biochemical pharmacology.

Identification of cytochrome P450 enzymes involved in the metabolism of 3′,4′-methylenedioxy-α-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes

H. Maurer, T. Kraemer, R. Staack, 2005, Xenobiotica; the fate of foreign compounds in biological systems.

Fenproporex N-dealkylation to amphetamine--enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats.

F. Peters, H. Maurer, T. Kraemer, 2004, Biochemical pharmacology.

Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes.

H. Maurer, T. Kraemer, R. Staack, 2004, Biochemical pharmacology.

Identification of cytochrome P450 enzymes involved in the metabolism of 4′-methoxy-α-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes

H. Maurer, T. Kraemer, R. Staack, 2003, Xenobiotica; the fate of foreign compounds in biological systems.

Development of the first metabolite-based LC-MSn urine drug screening procedure-exemplified for antidepressants

M. Meyer, H. Maurer, A. Weber, 2011, Analytical and bioanalytical chemistry.

GC-MS, LC-MSn, LC-high resolution-MSn, and NMR studies on the metabolism and toxicological detection of mesembrine and mesembrenone, the main alkaloids of the legal high “Kanna” isolated from Sceletium tortuosum

H. Maurer, J. Zapp, Golo M. J. Meyer, 2014, Analytical and Bioanalytical Chemistry.

What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse?

M. Meyer, H. Maurer, Lea Wagmann, 2016, Toxicology letters.

Current applications of high-resolution mass spectrometry in drug metabolism studies

M. Meyer, H. Maurer, 2012, Analytical and Bioanalytical Chemistry.

The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers

M. Meyer, F. Peters, H. Maurer, 2009, Drug Metabolism and Disposition.

Analysis of toxic alkaloids in body samples.

O. Drummer, H. Maurer, J. Beyer, 2009, Forensic science international.

Detection and validated quantification of toxic alkaloids in human blood plasma--comparison of LC-APCI-MS with LC-ESI-MS/MS.

F. Peters, H. Maurer, T. Kraemer, 2007, Journal of mass spectrometry : JMS.

Convenient Gram-Scale Metabolite Synthesis by Engineered Fission Yeast Strains Expressing Functional Human P450 Systems

P. Bour, F. Peters, H. Maurer, 2011, Applied biochemistry and biotechnology.

1 , 2-Diphenylethylamine Designer Drugs Metabolism Studies and Toxicological Analysis Using Gas Chromatography-Mass Spectrometry and Liquid Chromatography-Mass Spectrometry Coupled to Low and High Resolution-Mass Spectrometry

R. Hartmann, H. Maurer, Sancta Simplicitas, 2016 .

Cytochrome P450 isoenzymes involved in rat liver microsomal metabolism of californine and protopine.

H. Maurer, T. Kraemer, R. Staack, 2004, European journal of pharmacology.

Screening for Detection of New Antidepressants, Neuroleptics, Hypnotics, and Their Metabolites in Urine by GC-MS Developed Using Rat Liver Microsomes

H. Maurer, J. Bickeboeller-Friedrich, Joerg Bickeboeller-Friedrich, 2001, Therapeutic drug monitoring.

Validated electrospray liquid chromatographic–mass spectrometric assay for the determination of the mushroom toxins α- and β-amanitin in urine after immunoaffinity extraction

C. J. Schmitt, H. Maurer, T. Kraemer, 2000 .

Toxicokinetic studies of the four new psychoactive substances 4-chloroethcathinone, N-ethylnorpentylone, N-ethylhexedrone, and 4-fluoro-alpha-pyrrolidinohexiophenone

Sascha K. Manier, M. Meyer, H. Maurer, 2019, Forensic Toxicology.

In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks.

M. Meyer, H. Maurer, S. Brandt, 2017, Toxicology letters.

CYP21-catalyzed production of the long-term urinary metandienone metabolite 17β-hydroxymethyl-17α-methyl-18-norandrosta-1,4,13-trien-3-one: a contribution to the fight against doping

W. Schänzer, M. Parr, N. Schlörer, 2010, Biological chemistry.

Amphetamine-Derived New Psychoactive Substances : Metabolic Fate and Toxicological Detectability of Methiopropamine , three Methyl-Amphetamine Isomers , Camfetamine , 5-APB , 6-APB , 5-MAPB , and 6-MAPB in Urine and Human Liver Preparations Using

R. Hartmann, H. Maurer, merely tenacity, 2015 .

Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine

H. Maurer, T. Kraemer, 2005, Archives of Toxicology.

Metabolic fate and detectability of the new psychoactive substances 2‐(4‐bromo‐2,5‐dimethoxyphenyl)‐N‐[(2‐methoxyphenyl)methyl]ethanamine (25B‐NBOMe) and 2‐(4‐chloro‐2,5‐dimethoxyphenyl)‐N‐[(2‐methoxyphenyl)methyl]ethanamine (25C‐NBOMe) in human and rat urine by GC–MS, LC–MSn, and LC–HR–MS/MS approa

M. Meyer, H. Maurer, S. Brandt, 2017, Journal of pharmaceutical and biomedical analysis.

Current position of high-resolution MS for drug quantification in clinical & forensic toxicology.

M. Meyer, H. Maurer, A. Helfer, 2014, Bioanalysis.

A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 β-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches

M. Meyer, H. Maurer, S. Brandt, 2013, Analytical and Bioanalytical Chemistry.

Investigation on the Enantioselectivity of the Sulfation of the Methylenedioxymethamphetamine Metabolites 3,4-Dihydroxymethamphetamine and 4-Hydroxy-3-Methoxymethamphetamine using the Substrate-Depletion Approach

M. Meyer, H. Maurer, Andrea E. Schwaninger, 2011, Drug Metabolism and Disposition.

Herbal Drugs of Abuse

O. Drummer, H. Maurer, J. Beyer, 2009 .

Comprar Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites 2007, CD-ROM/Print | Hans H. Maurer | 9783527321469 | Wiley

H. Maurer, A. Weber, K. Pfleger, 2007 .

Development, Applicability, and Comparison of Bioassays for Metabolism of (New) Psychoactive Substances

T. Lehr, H. Maurer, A. Weber, 2018 .

Metabolism and Detectability of N-2-Methoxybenzyl- Substituted Phenethylamines in Urine and Human Liver Preparations by Hyphenated Low and High Resolution Mass Spectrometry

R. Hartmann, Meinen Eltern, M. Engel, 2018 .

Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes.

H. Maurer, T. Kraemer, R. Staack, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Short Communication IDENTIFICATION OF CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF 4-METHYL--PYRROLIDINOPROPIOPHENONE, A NOVEL SCHEDULED DESIGNER DRUG, IN HUMAN LIVER MICROSOMES

H. Maurer, 2003 .

Witnessed drug intake before planned denervation--always harmless?

M. Böhm, M. Meyer, F. Mahfoud, 2015, International journal of cardiology.

Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, "Eve") and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay.

K. Kovar, H. Maurer, H. Ensslin, 1996, Journal of chromatography. B, Biomedical applications.

On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry.

H. Maurer, 1996, Therapeutic drug monitoring.

In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases.

M. Meyer, H. Maurer, Lea Wagmann, 2018, Drug testing and analysis.

Direct Comparison of (±) 3,4-Methylenedioxymethamphetamine (“Ecstasy”) Disposition and Metabolism in Squirrel Monkeys and Humans

U. McCann, M. Huestis, G. Ricaurte, 2009, Therapeutic drug monitoring.

Nonlinear Pharmacokinetics of (±)3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) and Its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA That Develop After Typical Psychoactive Doses

U. McCann, G. Ricaurte, F. Peters, 2008, Journal of Pharmacology and Experimental Therapeutics.

Non-linear Pharmacokinetics of MDMA ( “ Ecstasy ” ) and its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA that Develop After Typical Psychoactive Doses

U. McCann, G. Ricaurte, F. Peters, 2008 .

Fast and simple procedure for liquid–liquid extraction of 136 analytes from different drug classes for development of a liquid chromatographic-tandem mass spectrometric quantification method in human blood plasma

M. Meyer, F. Peters, H. Maurer, 2010, Analytical and bioanalytical chemistry.

Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.

F. Peters, H. Maurer, T. Kraemer, 2004, Journal of mass spectrometry : JMS.

Quantification of 33 antidepressants by LC-MS/MS—comparative validation in whole blood, plasma, and serum

P. Schmidt, H. Maurer, M. Hopf, 2014, Analytical and Bioanalytical Chemistry.

Detection and quantification of benzodiazepines and Z-drugs in human whole blood, plasma, and serum samples as part of a comprehensive multi-analyte LC-MS/MS approach

P. Schmidt, H. Maurer, M. Hopf, 2013, Analytical and Bioanalytical Chemistry.

Development of an Automated Metabolite-based Liquid Chromatographic-High Resolution Tandem Mass Spectrometric Drug Screening Procedure for Urine and Blood Plasma

R. Hartmann, H. Maurer, W. Goethe, 2017 .

Amphetamine-derived Designer Drugs: Metabolism and Screening Procedures/Amphetamin-verwandte Designer-Drogen: Metabolismus und Screening Verfahren

H. Maurer, T. Kraemer, 2002 .

Biofilm inhibition by an experimental dental resin composite containing octenidine dihydrochloride.

M. Balkenhol, M. Hannig, H. Maurer, 2012, Dental materials : official publication of the Academy of Dental Materials.

Mass spectrometry for research and clinical implementation of TDM&CT

H. Maurer, 2017 .

Paper Spray Ionization Coupled to High Resolution Tandem Mass Spectrometry for Comprehensive Urine Drug Testing in Comparison to Liquid Chromatography-Coupled Techniques after Urine Precipitation or Dried Urine Spot Workup.

M. Meyer, H. Maurer, Julian A Michely, 2017, Analytical chemistry.

Pharmacokinetic studies on the ( synthetic ) cannabinoids JWH-210 , RCS-4 , and Δ 9-tetrahydrocannabinol in pigs

R. Hartmann, H. Maurer, 2016 .

Distribution of the (synthetic) cannabinoids JWH-210, RCS-4, as well as ∆9-tetrahydrocannabinol following pulmonary administration to pigs

P. Schmidt, M. Meyer, M. Menger, 2019, Archives of Toxicology.

Pitfalls in drug testing by hyphenated low- and high-resolution mass spectrometry.

H. Maurer, 2019, Drug testing and analysis.

Identification of antiarrhythmic drugs and their metabolites in urine

H. Maurer, 2005, Archives of Toxicology.

Chemistry, Pharmacology, Toxicology, and Hepatic Metabolism of Designer Drugs of the Amphetamine (Ecstasy), Piperazine, and Pyrrolidinophenone Types: A Synopsis

Roland F Staack, Dietmar Springer, Thomas Kraemer, 2004, Therapeutic drug monitoring.

Overview of Common Designer Drugs

M. Meyer, H. Maurer, Lilian H. J. Richter, 2019, Critical Issues in Alcohol and Drugs of Abuse Testing.

New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry.

H. Maurer, R. Staack, 2004, Journal of mass spectrometry : JMS.

Metabolism and toxicological detection of the new designer drug 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry.

H. Maurer, D. Springer, G. Fritschi, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Metabolism and toxicological detection of the new designer drug 4'-methoxy-alpha-pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry.

H. Maurer, D. Springer, G. Fritschi, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Studies on the metabolism and toxicological detection of the new designer drug 4'-methyl-α-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry

F. Peters, H. Maurer, D. Springer, 2002 .

Metabolism of racemic 3,4-methylenedioxyethylamphetamine in humans. Isolation, identification, quantification, and synthesis of urinary metabolites.

L. Hermle, K. Kovar, H. Maurer, 1996, Drug metabolism and disposition: the biological fate of chemicals.

Identification and quantification of ethylene glycol and diethylene glycol in plasma using gas chromatography-mass spectrometry

H. Maurer, C. Kessler, 1988, Archives of Toxicology.

The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic MDMA and its Enantiomers

M. Meyer, F. Peters, H. Maurer, 2008 .

Blood plasma level determination using an automated LC-MSn screening system and electronically stored calibrations exemplified for 22 drugs and two active metabolites often requested in emergency toxicology.

M. Meyer, H. Maurer, A. Caspar, 2018, Drug testing and analysis.

Dried urine spots - A novel sampling technique for comprehensive LC-MSn drug screening.

M. Meyer, H. Maurer, Julian A Michely, 2017, Analytica chimica acta.

Liquid chromatography-high resolution-tandem mass spectrometry using Orbitrap technology for comprehensive screening to detect drugs and their metabolites in blood plasma.

M. Meyer, H. Maurer, A. Weber, 2017, Analytica chimica acta.

LC-HR-MS/MS standard urine screening approach: Pros and cons of automated on-line extraction by turbulent flow chromatography versus dilute-and-shoot and comparison with established urine precipitation.

M. Meyer, H. Maurer, A. Weber, 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Simultaneous LC-MS/MS determination of JWH-210, RCS-4, ∆9-tetrahydrocannabinol, and their main metabolites in pig and human serum, whole blood, and urine for comparing pharmacokinetic data

M. Kettner, P. Schmidt, M. Menger, 2015, Analytical and Bioanalytical Chemistry.

Application of a UHPLC MS/MS–Based Multianalyte Approach for Screening and Validated Quantification of Drugs in Human Blood Plasma Often Requested in the Context of Brain Death Diagnosis

M. Meyer, H. Maurer, D. Remane, 2014, Therapeutic drug monitoring.

Direct analysis of the mushroom poisons α- and β-amanitin in human urine using a novel on-line turbulent flow chromatography mode coupled to liquid chromatography-high resolution-mass spectrometry/mass spectrometry.

M. Meyer, H. Maurer, Julian A Michely, 2014, Journal of chromatography. A.

Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract

M. Meyer, A. Becker, H. Maurer, 2013, Psychopharmacology.

Doping Control Analysis of Methoxyphenamine Using Liquid Chromatography-Tandem Mass Spectrometry

M. Thevis, W. Schänzer, H. Maurer, 2008, European journal of mass spectrometry.

Detection and validated quantification of nine herbal phenalkylamines and methcathinone in human blood plasma by LC-MS/MS with electrospray ionization.

F. Peters, H. Maurer, T. Kraemer, 2007, Journal of mass spectrometry : JMS.

Dimethocaine, a synthetic cocaine derivative: studies on its in vitro metabolism catalyzed by P450s and NAT2.

M. Meyer, H. Maurer, Carina Lindauer, 2014, Toxicology letters.

High-resolution mass spectrometry in toxicology: current status and future perspectives

M. Meyer, H. Maurer, 2016, Archives of Toxicology.

Screening for library-assisted identification and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization.

F. Peters, H. Maurer, C. Kratzsch, 2004, Journal of chromatography. A.

Systematic toxicological analysis procedures for acidic drugs and/or metabolites relevant to clinical and forensic toxicology and/or doping control.

H. Maurer, Hans H. Maurer, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Identification and differentiation of beta-blockers and their metabolites in urine by computerized gas chromatography-mass spectrometry.

H. Maurer, K. Pfleger, 1986, Journal of chromatography.

Contribution of human esterases to the metabolism of selected drugs of abuse.

M. Meyer, H. Maurer, A. Schütz, 2015, Toxicology letters.

Role of Gas Chromatography–Mass Spectrometry With Negative Ion Chemical Ionization in Clinical and Forensic Toxicology, Doping Control, and Biomonitoring

H. Maurer, 2002, Therapeutic drug monitoring.

Designer drug 2,5-dimethoxy-4-methyl-amphetamine (DOM, STP): involvement of the cytochrome P450 isoenzymes in formation of its main metabolite and detection of the latter in rat urine as proof of a drug intake using gas chromatography-mass spectrometry.

Michael Puetz, H. Maurer, A. H. Ewald, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse.

M. Meyer, H. Maurer, 2011, Pharmacogenomics.

Hyphenated mass spectrometric techniques-indispensable tools in clinical and forensic toxicology and in doping control.

H. Maurer, 2006, Journal of mass spectrometry : JMS.

Abuse of Nutmeg (Myristica fragrans Houtt.): Studies on the Metabolism and the Toxicologic Detection of its Ingredients Elemicin, Myristicin, and Safrole in Rat and Human Urine Using Gas Chromatography/Mass Spectrometry

H. Maurer, J. Beyer, D. Ehlers, 2006, Therapeutic drug monitoring.

Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation.

H. Maurer, T. Kraemer, F. X. Tauvel, 2001, Journal of analytical toxicology.

Identification of phenothiazine antihistamines and their metabolites in urine

H. Maurer, K. Pfleger, 2004, Archives of Toxicology.

Screening procedure for detection of phenothiazine and analogous neuroleptics and their metabolites in urine using a computerized gas chromatographic-mass spectrometric technique.

H. Maurer, K. Pfleger, 1984, Journal of chromatography.

In situ antibiofilm effect of glass-ionomer cement containing dimethylaminododecyl methacrylate.

M. Meyer, Xuedong Zhou, M. Hannig, 2015, Dental materials : official publication of the Academy of Dental Materials.

Identification and differentiation of benzodiazepines and their metabolites in urine by computerized gas chromatography-mass spectrometry.

H. Maurer, K. Pfleger, Hans Maurer, 1987, Journal of chromatography.

Studies on the metabolism and toxicological detection of the Eschscholtzia californica alkaloids californine and protopine in urine using gas chromatography-mass spectrometry.

H. Maurer, L. D. Paul, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.

F. Peters, H. Maurer, T. Kraemer, 2003, Journal of mass spectrometry : JMS.

Sulfation of the 3,4-methylenedioxymethamphetamine (MDMA) metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and their capability to inhibit human sulfotransferases.

M. Meyer, H. Maurer, J. Zapp, 2011, Toxicology letters.

The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers

M. Meyer, F. Peters, H. Maurer, 2008, Drug Metabolism and Disposition.

Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS.

N. Samyn, F. Peters, G. de Boeck, 2003, Journal of analytical toxicology.

Hyphenated high-resolution mass spectrometry—the “all-in-one” device in analytical toxicology?

H. Maurer, 2020, Analytical and Bioanalytical Chemistry.

Relevance of published blood concentrations of new psychoactive substance for rational case interpretation

H. Maurer, Jessica Welter-Luedeke, 2018, WIREs Forensic Science.

Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC-MS, LC-MSn , and LC-HR-MS/MS.

M. Meyer, H. Maurer, S. Brandt, 2018, Drug testing and analysis.

New Psychoactive Substances 3-Methoxyphencyclidine (3-MeO-PCP) and 3-Methoxyrolicyclidine (3-MeO-PCPy): Metabolic Fate Elucidated with Rat Urine and Human Liver Preparations and their Detectability in Urine by GC-MS, “LC-(High Resolution)-MSn” and “LC-(High Resolution)-MS/MS”

Sascha K. Manier, J. Wallach, H. Maurer, 2017, Current neuropharmacology.

Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices - Where do we stand today?

Markus R Meyer, Hans H Maurer, M. Meyer, 2016, Analytica chimica acta.

Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC-MS, LC-MSn , and LC-HR-MSn.

H. Maurer, J. Zapp, Julian A Michely, 2016, Drug testing and analysis.

Qualitative studies on the metabolism and the toxicological detection of the fentanyl-derived designer drugs 3-methylfentanyl and isofentanyl in rats using liquid chromatography–linear ion trap–mass spectrometry (LC-MSn)

M. Meyer, J. Dinger, H. Maurer, 2011, Analytical and Bioanalytical Chemistry.

Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases.

M. Meyer, H. Maurer, S. Brandt, 2018, Drug testing and analysis.

Ion suppression and enhancement effects of co-eluting analytes in multi-analyte approaches: systematic investigation using ultra-high-performance liquid chromatography/mass spectrometry with atmospheric-pressure chemical ionization or electrospray ionization.

M. Meyer, H. Maurer, D. Wissenbach, 2010, Rapid communications in mass spectrometry : RCM.

A validated GC-MS procedure for fast, simple, and cost-effective quantification of glycols and GHB in human plasma and their identification in urine and plasma developed for emergency toxicology

M. Meyer, H. Maurer, A. Weber, 2011, Analytical and bioanalytical chemistry.

Multi-analyte procedures for screening for and quantification of drugs in blood, plasma, or serum by liquid chromatography-single stage or tandem mass spectrometry (LC-MS or LC-MS/MS) relevant to clinical and forensic toxicology.

H. Maurer, 2005, Clinical biochemistry.

From the "Clinical Toxicology" committee of the GTFCh GC-MS Detection of Dihydroergotamine Artifact - Proof of Ingestion of Dihydroergotamine ?

F. Peters, H. Maurer, J. Beyer, 2005 .

Validated gas chromatographic-mass spectrometric assay for determination of the antifreezes ethylene glycol and diethylene glycol in human plasma after microwave-assisted pivalylation.

F. Peters, H. Maurer, T. Kraemer, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Chiral drug analysis using mass spectrometric detection relevant to research and practice in clinical and forensic toxicology.

M. Meyer, H. Maurer, Andrea E. Schwaninger, 2012, Journal of chromatography. A.

Methylenedioxy designer drugs: mass spectrometric characterization of their glutathione conjugates by means of liquid chromatography-high-resolution mass spectrometry/mass spectrometry and studies on their glutathionyl transferase inhibition potency.

M. Meyer, H. Maurer, Lilian H. J. Richter, 2014, Analytica chimica acta.

Screening procedure for detection of dihydropyridine calcium channel blocker metabolites in urine as part of a systematic toxicological analysis procedure for acidic compounds by gas chromatography-mass spectrometry after extractive methylation.

H. Maurer, J. W. Arlt, 1999, Journal of analytical toxicology.

Screening Procedure for Detection of Stimulant Laxatives and/or Their Metabolites in Human Urine Using Gas Chromatography-Mass Spectrometry after Enzymatic Cleavage of Conjugates and Extractive Methylation

F. Peters, H. Maurer, J. Beyer, 2005, Therapeutic drug monitoring.

Evaluation of novel organosilane modifications of paper spray mass spectrometry substrates for analyzing polar compounds.

Sascha K. Manier, M. Meyer, Marc Schneider, 2019, Talanta.

Validated electrospray liquid chromatographic-mass spectrometric assay for the determination of the mushroom toxins alpha- and beta-amanitin in urine after immunoaffinity extraction.

C. J. Schmitt, H. Maurer, T. Kraemer, 2000, Journal of chromatography. B, Biomedical sciences and applications.

New Bühlmann ELISA for determination of Amanitins in urine - Are there false positive results due to interferences with ur ine matrix, drugs or their metabolites?

H. Maurer, R. Staack, 2000 .

Identification and differentiation of alkylamine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry.

H. Maurer, K. Pfleger, 1988, Journal of chromatography.

Screening procedure for the detection of opioids, other potent analgesics and their metabolites in urine using a computerized gas chromatographic-mass spectrometric technique

H. Maurer, K. Pfleger, 1984 .

Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents

M. Meyer, H. Maurer, 2011, Analytical and Bioanalytical Chemistry.

Hydrolysis of 3,4-methylenedioxymethamphetamine (MDMA) metabolite conjugates in human, squirrel monkey, and rat plasma

M. Huestis, G. Ricaurte, F. Peters, 2009, Analytical and bioanalytical chemistry.

Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse.

M. Meyer, J. Dinger, H. Maurer, 2014, Toxicology letters.

Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS.

M. Meyer, H. Maurer, F. Schuster, 2010, Journal of mass spectrometry : JMS.

Chromatography of histamine H1- and H2-receptor blockers in biosamples.

H. Maurer, 1990, Journal of chromatography.

Production of human phase 1 and 2 metabolites by whole-cell biotransformation with recombinant microbes.

M. Meyer, A. Zöllner, F. Peters, 2010, Bioanalysis.

Development and application of a strategy for analyzing eight biomarkers in human urine to verify toxic mushroom or ricinus communis ingestions by means of hydrophilic interaction LC coupled to HRMS/MS.

M. Meyer, H. Maurer, A. Weber, 2020, Talanta.

Validated assay for quantification of oxcarbazepine and its active dihydro metabolite 10-hydroxycarbazepine in plasma by atmospheric pressure chemical ionization liquid chromatography/mass spectrometry.

F. Peters, H. Maurer, T. Kraemer, 2002, Journal of mass spectrometry : JMS.

Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS.

M. Meyer, H. Maurer, Golo M. J. Meyer, 2014, Drug testing and analysis.

Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) in toxicological analysis. Studies on the detection of clobenzorex and its metabolites within a systematic toxicological analysis procedure by GC-MS and by immunoassay and studies on the detection of alp

C. J. Schmitt, O. Ledvinka, H. Maurer, 1997, Journal of chromatography. B, Biomedical sciences and applications.

New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques.

M. Meyer, F. Peters, H. Maurer, 2009, Journal of mass spectrometry : JMS.

Identification of Cytochrome P450 Enzymes Involved in the Metabolism of the New Designer Drug 4′-Methyl-α-pyrrolidinobutyrophenone

M. Meyer, F. Peters, H. Maurer, 2008, Drug Metabolism and Disposition.

Studies on the Metabolism and Toxico- logical Analysis of the new Designer Drug α-Pyrrolidino-valerophenone (PVP) in Rat Urine Using GC-MS Tech- niques

M. Meyer, F. Peters, H. Maurer, 2008 .

In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step

H. Maurer, T. Kraemer, R. Staack, 2004, Xenobiotica; the fate of foreign compounds in biological systems.

Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series).

H. Maurer, D. S. Theobald, 2007, Biochemical pharmacology.

New designer drug, 2,5-dimethoxy-4-propylthio-beta-phenethylamine (2C-T-7): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry.

H. Maurer, D. S. Theobald, S. Fehn, 2005, Journal of mass spectrometry : JMS.

What is the future of (ultra) high performance liquid chromatography coupled to low and high resolution mass spectrometry for toxicological drug screening?

Hans H Maurer, H. Maurer, 2013, Journal of chromatography. A.

Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry.

F. Peters, H. Maurer, T. Kraemer, 2003, Journal of mass spectrometry : JMS.

Negative-ion chemical ionization gas chromatography-mass spectrometry assay for enantioselective measurement of amphetamines in oral fluid: application to a controlled study with MDMA and driving under the influence cases.

W. Riedel, N. Samyn, F. Peters, 2007, Clinical chemistry.

Development, Validation, and Application of a Fast and Simple GC–MS Method for Determination of Some Therapeutic Drugs Relevant in Emergency Toxicology

M. Meyer, H. Maurer, A. Weber, 2011, Therapeutic drug monitoring.

Mass Spectrometry for Research and Application in Therapeutic Drug Monitoring or Clinical and Forensic Toxicology

H. Maurer, 2018, Therapeutic drug monitoring.

Is adipose tissue suitable for detection of (synthetic) cannabinoids? A comparative study analyzing antemortem and postmortem specimens following pulmonary administration of JWH-210, RCS-4, as well as ∆9-tetrahydrocannabinol to pigs

P. Schmidt, M. Meyer, M. Menger, 2020, Archives of Toxicology.

New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine.

C. Vollmar, M. Meyer, E. Wolf, 2012, Journal of mass spectrometry : JMS.

Toxicological detection of pholcodine and its metabolites in urine and hair using radio immunoassay, fluorescence polarisation immunoassay, enzyme immunoassay and gas chromatography-mass spectrometry

H. Maurer, C. F. Fritz, 2005, International Journal of Legal Medicine.

Metabolism and toxicological detection of the designer drug N-(1-phenylcyclohexyl)-3-methoxypropanamine (PCMPA) in rat urine using gas chromatography-mass spectrometry.

F. Peters, H. Maurer, C. Sauer, 2008, Forensic science international.

Metabolism and toxicological detection of a new designer drug, N-(1-phenylcyclohexyl)propanamine, in rat urine using gas chromatography-mass spectrometry.

F. Peters, H. Maurer, C. Sauer, 2008, Journal of chromatography. A.

New designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques.

F. Peters, H. Maurer, C. Sauer, 2008, Journal of mass spectrometry : JMS.

Metabolism and toxicological detection of the designer drug 4-iodo-2,5-dimethoxy-amphetamine (DOI) in rat urine using gas chromatography-mass spectrometry.

H. Maurer, A. H. Ewald, G. Fritschi, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B) in rat urine using gas chromatography-mass spectrometry.

H. Maurer, D. S. Theobald, G. Fritschi, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Studies on the metabolism and toxicological detection of the designer drug 2,5‐dimethoxy‐4‐methyl‐β‐ phenethylamine (2C‐D) in rat urine using gas chromatographic/mass spectrometric techniques

H. Maurer, D. S. Theobald, 2006 .

Studies on the metabolism and toxicological detection of the designer drug 4-ethyl-2,5-dimethoxy-beta-phenethylamine (2C-E) in rat urine using gas chromatographic-mass spectrometric techniques.

H. Maurer, D. S. Theobald, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

New designer drug N-(1-phenylcyclohexyl)-3-ethoxypropanamine (PCEPA): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques.

F. Peters, H. Maurer, C. Sauer, 2006, Journal of mass spectrometry : JMS.

New designer drug 4-iodo-2,5-dimethoxy-beta-phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric and capillary electrophoretic/mass spectrometric techniques.

M. Pütz, E. Schneider, H. Maurer, 2006, Journal of mass spectrometry : JMS.

Designer drugs 2,5-dimethoxy-4-bromo-amphetamine (DOB) and 2,5-dimethoxy-4-bromo-methamphetamine (MDOB): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques.

H. Maurer, A. H. Ewald, G. Fritschi, 2006, Journal of mass spectrometry : JMS.

Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry.

Frank T Peters, Hans H Maurer, F. Peters, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

New designer drug 2,5-dimethoxy-4-ethylthio-beta-phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry.

Michael Puetz, H. Maurer, R. Staack, 2005, Journal of mass spectrometry : JMS.

New designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine.

H. Maurer, R. Staack, Gieselher Fritschi, 2003, Journal of mass spectrometry : JMS.

Mass spectral and GC data of drugs, poisons, pesticides, pollutants and their metabolites: Part 3 mass spectra (m/z222 to 777 amu).

Karl Pfleger, Hans H. Maurer, Armin A. Weber, 1992 .

Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology.

T. Lehr, M. Kettner, P. Schmidt, 2016, Toxicology letters.

Time- and temperature-dependent postmortem concentration changes of the (synthetic) cannabinoids JWH-210, RCS-4, as well as ∆9-tetrahydrocannabinol following pulmonary administration to pigs

P. Schmidt, M. Meyer, M. Menger, 2020, Archives of Toxicology.

Can toxicokinetics of (synthetic) cannabinoids in pigs after pulmonary administration be upscaled to humans by allometric techniques?

T. Lehr, P. Schmidt, M. Meyer, 2018, Biochemical pharmacology.

Distribution of Synthetic Cannabinoids JWH-210, RCS-4 and ∆ 9-Tetrahydrocannabinol After Intravenous Administration to Pigs

M. Kettner, P. Schmidt, M. Menger, 2017, Current neuropharmacology.

Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated using LC-HR-MS/MS: Do they reflect patterns in humans?

M. Kettner, P. Schmidt, M. Meyer, 2017, Drug testing and analysis.

Can JWH-210 and JWH-122 be detected in adipose tissue four weeks after single oral drug administration to rats?

P. Schmidt, H. Maurer, N. Schaefer, 2014, Biomedical chromatography : BMC.

Bioequivalence of sodium monofluorophosphate with sodium fluoride and compatibility with calcium.

H. Maurer, I. Setnikar, 1990, Arzneimittel-Forschung.

Relative bioavailability of fluoride from monofluorophosphate tablets after single oral administration.

H. Maurer, I. Setnikar, 1990, Arzneimittel-Forschung.

The breast feeding mother and xenon anaesthesia: four case reports. Breast feeding and xenon anaesthesia

M. Meyer, H. Maurer, R. Stuttmann, 2010, BMC anesthesiology.

Metabolism of pholcodine in man.

H. Maurer, C. F. Fritz, 1990, Arzneimittel-Forschung.

Efficient cleavage of conjugates of drugs or poisons by immobilized beta-glucuronidase and arylsulfatase in columns.

S. Toennes, H. Maurer, 1999, Clinical chemistry.

Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry.

F. Peters, H. Maurer, T. Kraemer, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MSn techniques

M. Meyer, H. Maurer, S. Brandt, 2015, Analytical and Bioanalytical Chemistry.

Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MSn techniques

M. Meyer, H. Maurer, P. Kavanagh, 2015, Analytical and Bioanalytical Chemistry.

Comparison of Urinary On-Site Immunoassay Screening and Gas Chromatography-Mass Spectrometry Results of 111 Patients With Suspected Poisoning Presenting at an Emergency Department

M. Meyer, F. Peters, H. Maurer, 2007, Therapeutic drug monitoring.

Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy').

F. Peters, H. Maurer, T. Kraemer, 2000, Toxicology letters.

Toxicological detection of ajmaline, prajmaline and their metabolites in urine integrated in a “general-unknown” analysis procedure using gas chromatography-mass spectrometry

H. Maurer, K. Pfleger, 1988 .

New designer drug p-methoxymethamphetamine: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry.

H. Maurer, R. Staack, J. Fehn, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The antispasmodic drug mebeverine leads to positive amphetamine results by fluorescence polarization immunoassay (FPIA)--studies on the toxicological analysis of urine by FPIA and GC-MS.

R. Wennig, H. Maurer, T. Kraemer, 2001, Journal of analytical toxicology.

Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drug–drug interactions of drugs of abuse

M. Meyer, H. Maurer, Lea Wagmann, 2018, Archives of Toxicology.

In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach

M. Meyer, J. Dinger, H. Maurer, 2016, Archives of Toxicology.

Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers.

M. Meyer, F. Peters, H. Maurer, 2009, Biochemical pharmacology.

New Psychoactive Substances: Chemistry, Pharmacology, Metabolism, and Detectability of Amphetamine Derivatives With Modified Ring Systems

H. Maurer, Jessica Welter-Luedeke, 2016, Therapeutic drug monitoring.

Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine.

H. Maurer, T. Kraemer, R. Staack, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Systematic investigation of ion suppression and enhancement effects of fourteen stable-isotope-labeled internal standards by their native analogues using atmospheric-pressure chemical ionization and electrospray ionization and the relevance for multi-analyte liquid chromatographic/mass spectrometric

M. Meyer, H. Maurer, D. Wissenbach, 2010, Rapid communications in mass spectrometry : RCM.

Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography–mass spectrometry

Frank T Peters, Markus R Meyer, Hans H Maurer, 2010, Analytical and bioanalytical chemistry.

Environmental risk assessment of medicinal products for human use according to European Commission recommendations

G. Huschek, H. Maurer, P. Hansen, 2004, Environmental toxicology.

Power of Orbitrap-based LC-high resolution-MS/MS for comprehensive drug testing in urine with or without conjugate cleavage or using dried urine spots after on-spot cleavage in comparison to established LC-MSn or GC-MS procedures.

M. Meyer, H. Maurer, Julian A Michely, 2018, Drug testing and analysis.

Colchicine Poisoning after Mix-up of Ramsons ( Allium ursinum L.) and Meadow Saffron ( Colchicum autumnale L.)

F. Peters, H. Maurer, J. Beyer, 2004 .

Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry.

H. Maurer, R. Staack, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Low resolution and high resolution MS for studies on the metabolism and toxicological detection of the new psychoactive substance methoxypiperamide (MeOP).

M. Meyer, H. Maurer, P. Kavanagh, 2015, Journal of mass spectrometry : JMS.

Drugs of Abuse (Including Designer Drugs)

M. Meyer, H. Maurer, 2012 .

Studies on the Human Metabolism and the Toxicologic Detection of the Cough Suppressant Dropropizine in Urine Using Gas Chromatography-Mass Spectrometry

H. Maurer, R. Staack, D. S. Theobald, 2004, Therapeutic drug monitoring.

Studies on the metabolism and the toxicological analysis of the nootropic drug fipexide in rat urine using gas chromatography-mass spectrometry.

H. Maurer, R. Staack, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone.

H. Maurer, R. Staack, 2003, Journal of analytical toxicology.

Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry.

H. Maurer, R. Staack, G. Fritschi, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Screening procedures for simultaneous detection of several drug classes used for high throughput toxicological analyses and doping control. A review.

H. Maurer, H H Maurer, 2000, Combinatorial chemistry & high throughput screening.

Screening procedure for detection of antidepressants of the selective serotonin reuptake inhibitor type and their metabolites in urine as part of a modified systematic toxicological analysis procedure using gas chromatography-mass spectrometry.

H. Maurer, H H Maurer, J Bickeboeller-Friedrich, 2000, Journal of analytical toxicology.

Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine.

H. Maurer, T. Kraemer, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Studies on the metabolism and toxicological detection of the amphetamine-like anorectic mefenorex in human urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay.

I. Vernaleken, H. Maurer, T. Kraemer, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers.

M. Meyer, F. Peters, H. Maurer, 2009, Toxicology letters.

Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine.

M. Meyer, F. Peters, H. Maurer, 2009, Biochemical pharmacology.

2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.

H. Maurer, A. H. Ewald, 2008, Toxicology letters.

A systematic comparison of four different workup procedures for systematic toxicological analysis of urine samples using gas chromatography–mass spectrometry

W. Haefeli, F. Peters, H. Maurer, 2009, Analytical and bioanalytical chemistry.

Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance

G. Grassi, M. Böhm, U. Laufs, 2015, Journal of hypertension.

Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology.

Markus R Meyer, Hans H Maurer, M. Meyer, 2016, Bioanalysis.

Toward High-Throughput Drug Screening Using Mass Spectrometry

Frank T Peters, Hans H Maurer, F. Peters, 2005, Therapeutic drug monitoring.

The Role of Human UDP-Glucuronyltransferases on the Formation of the Methylenedioxymethamphetamine (Ecstasy) Phase II Metabolites R- and S-3-Methoxymethamphetamine 4-O-Glucuronides

M. Meyer, H. Maurer, J. Zapp, 2009, Drug Metabolism and Disposition.

The Role of Human UDP-glucuronyltransferases on the Formation of the Methylenedioxymethamphetamine (Ecstasy) Phase II Metabolites R - and S -3-methoxymethamphetamine 4- O -glucuronides

M. Meyer, H. Maurer, J. Zapp, 2009 .

Investigations on the stereoselectivity of the phase II metabolism of the 3,4-methylenedioxyethylamphetamine (MDEA) metabolites 3,4-dihydroxyethylamphetamine (DHEA) and 4-hydroxy-3-methoxyethylamphetamine (HMEA).

M. Meyer, H. Maurer, J. Zapp, 2012, Toxicology letters.

Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for enantioselective measurement of the designer drugs MDEA, MDMA, and MDA and its application to samples from a controlled study with MDMA.

Frank T Peters, Thomas Kraemer, Hans H Maurer, 2005, Clinical chemistry.

Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxicology cases.

Frank T Peters, Thomas Kraemer, Hans H Maurer, 2002, Clinical chemistry.

Monitoring of kratom or Krypton intake in urine using GC-MS in clinical and forensic toxicology

M. Meyer, H. Maurer, A. Weber, 2011, Analytical and bioanalytical chemistry.

Identification and differentiation of barbiturates, other sedative-hypnotics and their metabolites in urine integrated in a general screening procedure using computerized gas chromatography-mass spectrometry.

H. Maurer, 1990, Journal of chromatography.

Toxicokinetics of Drugs of Abuse: Current Knowledge of the Isoenzymes Involved in the Human Metabolism of Tetrahydrocannabinol, Cocaine, Heroin, Morphine, and Codeine

H. Maurer, C. Sauer, D. S. Theobald, 2006, Therapeutic drug monitoring.

Bioanalytical method validation and its implications for forensic and clinical toxicology – A review

Frank T. Peters, Hans H. Maurer, F. Peters, 2002 .

Objective assessment of nonadherence and unknown co-medication in hospitalized patients

W. Haefeli, M. Meyer, I. Walter‐Sack, 2012, European Journal of Clinical Pharmacology.

Cytotoxicity of new psychoactive substances and other drugs of abuse studied in human HepG2 cells using an adopted high content screening assay.

A. Beck, V. Flockerzi, M. Meyer, 2019, Toxicology letters.

Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drug–drug interactions of drugs of abuse

M. Meyer, H. Maurer, Lea Wagmann, 2018, Archives of Toxicology.

P-glycoprotein interactions of novel psychoactive substances - stimulation of ATP consumption and transport across Caco-2 monolayers.

M. Meyer, C. Lehr, B. Loretz, 2015, Biochemical pharmacology.

Refined protocols of tamoxifen injection for inducible DNA recombination in mouse astroglia

F. Kirchhoff, A. Verkhratsky, H. Maurer, 2018, Scientific Reports.

An automated screening method for drugs and toxic compounds in human serum and urine using liquid chromatography-tandem mass spectrometry.

A. Scholer, H. Maurer, F. Hammann, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of a fast and simple multi-analyte procedure for quantification of 40 drugs relevant to emergency toxicology using GC-MS and one-point calibration.

Golo M J Meyer, Armin A Weber, Hans H Maurer, 2013, Drug testing and analysis.

How Can Analytical Diagnostics in Clinical Toxicology Be Successfully Performed Today?

H. Maurer, 2012, Therapeutic drug monitoring.

Towards a universal LC-MS screening procedure - can an LIT LC-MS(n) screening approach and reference library be used on a quadrupole-LIT hybrid instrument?

Frank T Peters, Markus R Meyer, Armin A Weber, 2012, Journal of mass spectrometry : JMS.

High prevalence of unknown co-medication in hospitalised patients

W. Haefeli, I. Walter‐Sack, M. Martin-Facklam, 2004, European Journal of Clinical Pharmacology.

Toxicokinetics of novel psychoactive substances: characterization of N-acetyltransferase (NAT) isoenzymes involved in the phase II metabolism of 2C designer drugs.

M. Meyer, H. Maurer, A. Robert, 2014, Toxicology letters.

oxicokinetics of novel psychoactive substances : Characterization of-acetyltransferase ( NAT ) isoenzymes involved in the phase II etabolism of 2 C designer drugs

H. Maurer, A. Meyer, A. Robert, 2014 .

Screening Procedure for Detection of Diuretics and Uricosurics and/or Their Metabolites in Human Urine Using Gas Chromatography-Mass Spectrometry After Extractive Methylation

F. Peters, H. Maurer, J. Beyer, 2005, Therapeutic Drug Monitoring.

Automated mass spectral deconvolution and identification system for GC-MS screening for drugs, poisons, and metabolites in urine.

Frank T Peters, Markus R Meyer, Hans H Maurer, 2010, Clinical chemistry.

Different in vitro and in vivo tools for elucidating the human metabolism of alpha-cathinone-derived drugs of abuse.

Sascha K. Manier, M. Meyer, H. Maurer, 2018, Drug testing and analysis.

An easy and fast adenosine 5'-diphosphate quantification procedure based on hydrophilic interaction liquid chromatography-high resolution tandem mass spectrometry for determination of the in vitro adenosine 5'-triphosphatase activity of the human breast cancer resistance protein ABCG2.

M. Meyer, H. Maurer, Lea Wagmann, 2017, Journal of chromatography. A.

LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques

M. Meyer, H. Maurer, F. Westphal, 2017, Analytical and Bioanalytical Chemistry.

2-Methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques

M. Meyer, W. Weinmann, E. Wolf, 2013, Analytical and Bioanalytical Chemistry.

Studies on the metabolism and detectability of the designer drug β-naphyrone in rat urine using GC-MS and LC-HR-MS/MS.

M. Meyer, H. Maurer, D. Prosser, 2013, Drug testing and analysis.

Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches

M. Meyer, F. Noor, H. Maurer, 2016, Analytical and Bioanalytical Chemistry.

Demands on scientific studies in clinical toxicology.

H. Maurer, 2007, Forensic science international.

Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC-HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches.

D. Boels, M. Meyer, B. Lelièvre, 2015, Drug testing and analysis.

Studies on the metabolism of mitragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry.

H. Maurer, D. Wissenbach, Anika A. Philipp, 2009, Journal of mass spectrometry : JMS.

Detection of 4-hydroxycoumarin anticoagulants and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation.

H. Maurer, J. W. Arlt, 1998, Journal of chromatography. B, Biomedical sciences and applications.

High-resolution mass spectrometry

D. Muddiman, H. Maurer, 2012, Analytical and Bioanalytical Chemistry.

Development and validation of a multi-analyte LC-MS/MS approach for quantification of neuroleptics in whole blood, plasma, and serum.

P. Schmidt, H. Maurer, M. Hopf, 2016, Drug testing and analysis.

Systematic forensic toxicological analysis by GC-MS in serum using automated mass spectral deconvolution and identification system.

H. Maurer, H. Desel, M. Grapp, 2016, Drug Testing and Analysis.

Detection of anticonvulsants and their metabolites in urine within a “general unknown” analysis procedure using computerized gas chromatography-mass spectrometry

H. Maurer, 2005, Archives of Toxicology.

Mass spectral and GC data of drugs, poisons, and their metabolites

H. Maurer, A. Weber, K. Pfleger, 1985 .

Screening procedure for detecting butyrophenone and bisfluorophenyl neuroleptics in urine using a computerized gas chromatographic-mass spectrometric technique.

H. Maurer, K. Pfleger, 1983, Journal of chromatography.

Metabolism studies of the Kratom alkaloids mitraciliatine and isopaynantheine, diastereomers of the main alkaloids mitragynine and paynantheine, in rat and human urine using liquid chromatography-linear ion trap-mass spectrometry.

H. Maurer, A. Weber, D. Wissenbach, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Biotechnological synthesis of the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6--a versatile alternative to multistep chemical synthesis.

F. Peters, H. Maurer, J. Zapp, 2009, Journal of analytical toxicology.

Use of fission yeast heterologously expressing human cytochrome P450 2B6 in biotechnological synthesis of the designer drug metabolite N-(1-phenylcyclohexyl)-2-hydroxyethanamine.

F. Peters, H. Maurer, J. Zapp, 2009, Forensic science international.

Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinobutyrophenone.

M. Meyer, F. Peters, H. Maurer, 2007, Biochemical pharmacology.

Analytical characterization of bioactive N-benzyl-substituted phenethylamines and 5-methoxytryptamines.

N. Dempster, M. Meyer, H. Maurer, 2015, Rapid communications in mass spectrometry : RCM.

The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS(n.).

Folker Westphal, Markus R Meyer, Golo M J Meyer, 2014, Drug testing and analysis.

Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry.

H. Maurer, D. Springer, G. Fritschi, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Metabolism and toxicological detection of the new designer drug 3′,4′-methylenedioxy-α-pyrrolidinopropiophenone studied in urine using gas chromatography–mass spectrometry

H. Maurer, D. Springer, G. Fritschi, 2003 .

Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-α-pyrrolidinopropiophenone in urine using gas chromatography–mass spectrometry

F. Peters, H. Maurer, D. Springer, 2002 .

FC12 on the metabolism of the sweetener stevioside in humans

H. Maurer, T. Kraemer, 1994 .

insbesondere bei Intoxikationsfällen Determination of cause of death , especially in cases of intoxication

K. Rentsch, F. Peters, H. Maurer, 2005 .

Production and NMR analysis of the human ibuprofen metabolite 3-hydroxyibuprofen.

F. Peters, H. Maurer, J. Zapp, 2012, Journal of biotechnology.

Case report of accidental poisoning with the tranquilizer xylazine and the anesthetic ketamine confirmed by qualitative and quantitative toxicological analysis using GC-MS and LC-MS(n.).

M. Meyer, H. Maurer, Golo M. J. Meyer, 2013, Drug testing and analysis.

Toxicological detection of ibuprofen and its metabolites in urine using gas chromatography-mass spectrometry (GC-MS).

H. Maurer, T. Kraemer, A. Weber, 1994, Die Pharmazie.

Screening procedure for detection of antidepressants and their metabolites in urine using a computerized gas chromatographic--mass spectrometric technique.

H. Maurer, K. Pfleger, 1984, Journal of Chromatography A.

Toxicological detection of ethylenediamine and piperazine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry

H. Maurer, K. Pfleger, 1988 .

Screening procedure for the detection of antiparkinsonian drugs and their metabolites in urine using a computerized gas chromatographic-mass spectrometric technique

H. Maurer, K. Pfleger, 1985 .

Screening procedure for detecting anti-inflammatory analgesics and their metabolites in urine using a computerized gas-chromatographic-mass spectrometric technique

H. Maurer, K. Pfleger, 1983 .

High-resolution mass spectrometry in toxicology: current status and future perspectives

Markus R. Meyer, H. H. Maurer, M. Meyer, 2016, Archives of Toxicology.

Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MSn, and LC-high resolution-MS/MS

H. Maurer, J. Zapp, Golo M. J. Meyer, 2015, Analytical and Bioanalytical Chemistry.

Acute combined poisoning with the new designer drug 4-methyl-N-ethyl-cathinone (4-MEC) and gammabutyrolactone (GBL): A case report with different analytical approaches for identification of some metabolites

M. Meyer, B. Lelièvre, H. Maurer, 2014 .

Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein.

M. Meyer, H. Maurer, Tina Orschiedt, 2013, Toxicology letters.

Toxicokinetics of Emerging Drugs of Abuse : In vivo and in vitro studies on the metabolic fate of the cathinone-derived designer drug ß-naphyrone

H. Maurer, 2013 .

Metabolic fate of the new synthetic cannabinoid 7'N-5F-ADB in rat, human, and pooled human S9 studied by means of hyphenated high-resolution mass spectrometry.

M. Meyer, H. Maurer, Lilian H. J. Richter, 2018, Drug testing and analysis.

Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn

M. Meyer, M. Bach, H. Maurer, 2013, Analytical and Bioanalytical Chemistry.

Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration.

M. Huestis, M. Meyer, D. Gorelick, 2011, Clinical chemistry.

Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its metabolites 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3,4-methylenedioxyamphetamine in squirrel monkey and human plasm

M. Huestis, G. Ricaurte, F. Peters, 2009, Forensic science international.

Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans.

M. Huestis, M. Meyer, D. Gorelick, 2012, Biochemical pharmacology.

Human MDMA (Ecstasy) and Phase I and Phase II Metabolite Urinary Excretion Kinetics Following Controlled MDMA Administration

M. Huestis, M. Meyer, D. Gorelick, 2011 .

Amphetamine concentrations in human urine following single-dose administration of the calcium antagonist prenylamine-studies using fluorescence polarization immunoassay (FPIA) and GC-MS.

Frank T Peters, Thomas Kraemer, Hans H Maurer, 2003, Journal of analytical toxicology.

Use of liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry for studying the metabolism of paynantheine, an alkaloid of the herbal drug Kratom in rat and human urine

H. Maurer, A. Weber, D. Wissenbach, 2010, Analytical and bioanalytical chemistry.

Treatment of SEC62 over-expressing tumors by Thapsigargin and Trifluoperazine

M. Meyer, M. Menger, R. Zimmermann, 2018, Biomolecular concepts.

Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach.

M. Meyer, H. Maurer, A. Caspar, 2018, Toxicology letters.

Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy

K. Kleesiek, A. Holstein, A. Plaschke, 2003, European Journal of Clinical Pharmacology.

Title: An easy and fast adenosine 5′-diphosphate quantification procedure based on hydrophilic interaction liquid chromatography-high resolution tandem mass spectrometry for determination of the in vitro adenosine 5′- triphosphatase activity of the human breast cancer resistance protein ABCG2 Author

M. Meyer, H. Maurer, Lea Wagmann, 2020 .

Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MSn, and LC-HR-MS/MS

M. Meyer, V. Auwärter, H. Maurer, 2015, Analytical and Bioanalytical Chemistry.

Nano liquid chromatography-high-resolution mass spectrometry for the identification of metabolites of the two new psychoactive substances N-(ortho-methoxybenzyl)-3,4-dimethoxyamphetamine and N-(ortho-methoxybenzyl)-4-methylmethamphetamine.

M. Meyer, H. Maurer, A. Weber, 2018, Talanta.

Biotransformation and detectability of the designer drug 2,5-dimethoxy-4-propylphenethylamine (2C-P) studied in urine by GC-MS, LC-MSn, and LC-high-resolution-MSn

M. Meyer, H. Maurer, A. Turcant, 2014, Analytical and Bioanalytical Chemistry.

How can analytical diagnostics in clinical toxicology be successfully performed today?

H. Maurer, 2012, Therapeutic drug monitoring.

Studies on the metabolism and toxicological detection of the designer drug 2,5-dimethoxy-4-methyl-beta- phenethylamine (2C-D) in rat urine using gas chromatographic/mass spectrometric techniques.

H. Maurer, D. S. Theobald, 2006, Journal of mass spectrometry : JMS.

Coexpression of CPR from Various Origins Enhances Biotransformation Activity of Human CYPs in S. pombe

F. Bourgaud, F. Peters, H. Maurer, 2013, Applied Biochemistry and Biotechnology.

Screening procedure for the detection of alkanolamine antihistamines and their metabolites in urine using computerized gas chromatography-mass spectrometry.

H. Maurer, K. Pfleger, 1988, Journal of chromatography.

Mass spectral and GC data of drugs, poisons, pesticides, pollutants and their metabolites. Part 1: methods, tables, indexes.

H. Maurer, A. Weber, K. Pfleger, 1992 .

Metabolism of designer drugs of abuse.

Roland F Staack, Hans H Maurer, H. Maurer, 2005, Current drug metabolism.

Liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in rat brain.

G. Ricaurte, F. Peters, H. Maurer, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation.

M. Meyer, H. Maurer, 2009, Chemical research in toxicology.

Studies on the Metabolism and Toxicological Detection of the Designer Drug DOI in Rat Urine Using GC-MS Techniques

H. Maurer, A. H. Ewald, G. Fritschi, 2008 .

Biotechnological synthesis of drug metabolites using human cytochrome P450 isozymes heterologously expressed in fission yeast.

F. Peters, H. Maurer, M. Bureik, 2009, Bioanalysis.

Studies on the metabolism and detectability of the emerging drug of abuse diphenyl-2-pyrrolidinemethanol (D2PM) in rat urine using GC-MS and LC-HR-MS/MS.

M. Meyer, H. Maurer, S. Schmitt, 2013, Journal of mass spectrometry : JMS.

Phenethylamine-derived designer drug diphenyl-2-pyrrolidinemethanol (D2PM): Investigations of its biotransformation in rats

H. Maurer, 2013 .

Gas chromatographic-mass spectrometric procedures for determination of the catechol-O-methyltransferase (COMT) activity and for detection of unstable catecholic metabolites in human and rat liver preparations after COMT catalyzed in statu nascendi derivatization using S-adenosylmethionine.

H. Maurer, T. Kraemer, J. Bickeboeller-Friedrich, 2000, Journal of chromatography. B, Biomedical sciences and applications.

New designer drug 4'-methyl-alpha-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry.

F. Peters, H. Maurer, D. Springer, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

On the metabolism of ditazole in man.

H. Maurer, I. Kleff, 1988, Arzneimittel-Forschung.

Objective assessment of nonadherence and unknown co-medication in hospitalized patients

W. Haefeli, M. Meyer, I. Walter‐Sack, 2012, European Journal of Clinical Pharmacology.

Qualitative metabolism assessment and toxicological detection of xylazine, a veterinary tranquilizer and drug of abuse, in rat and human urine using GC–MS, LC–MSn, and LC–HR-MSn

H. Maurer, Golo M. J. Meyer, 2013, Analytical and Bioanalytical Chemistry.

Doxepin concentrations in plasma and cerebrospinal fluid

K. Fassbender, J. Spiegel, R. Schomburg, 2011, Journal of Neural Transmission.

Ultra high performance liquid chromatographic-tandem mass spectrometric multi-analyte procedure for target screening and quantification in human blood plasma: validation and application for 31 neuroleptics, 28 benzodiazepines, and Z-drugs

M. Meyer, H. Maurer, D. Wissenbach, 2011, Analytical and bioanalytical chemistry.

Engineering of Human CYP3A Enzymes by Combination of Activating Polymorphic Variants

F. Peters, H. Maurer, M. Bureik, 2012, Applied Biochemistry and Biotechnology.

Dimethocaine, a synthetic cocaine derivative: studies on its in vitro metabolism catalyzed by P450s and NAT2.

M. Meyer, H. Maurer, Carina Lindauer, 2014, Toxicology letters.